Michael L. Meyers

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

Paul B. Chapman, Lawrence H. Einhorn, Michael L. Meyers et al. · Journal of Clinical Oncology · 1999 · 763 citations

Medicine, Oncology, Pharmacology +11

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio et al. · Nature · 2023 · 468 citations · Full text

Medicine, Molecular Biology, Oncology +13

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21

Govindaswami Ragupathi, Michael L. Meyers, Sucharita Adluri et al. · International Journal of Cancer · 2000 · 125 citations

Medicine, Immunology, Oncology +16

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy

Matthew D. Hellmann, Pasi A. Jänne, Mateusz Opyrchal et al. · Clinical Cancer Research · 2020 · 124 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

Jonathan J. Lewis, Sylvia Janetzki, Susanne G. Schaed et al. · International Journal of Cancer · 2000 · 105 citations · Full text

Life Sciences, Immunology, Oncology +17